Bifidobacterium Animalis Research: the market size reached US$1196.2 million in 2024 and is expected to reach US$1267 million in 2025

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Bifidobacterium Animalis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bifidobacterium Animalis market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Bifidobacterium Animalis was estimated to be worth US$ 1196 million in 2024 and is forecast to a readjusted size of US$ 2044 million by 2031 with a CAGR of 8.3% during the forecast period 2025-2031.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4799219/bifidobacterium-animalis

Bifidobacterium Animalis Market Overview

Product Definition

Bifidobacteria animalis are a group of probiotics commonly found in the animal gut, belonging to the genus Bifidobacterium. They are characterized by growth under anaerobic or microaerophilic conditions and the production of lactic and acetic acids through the fermentation of carbohydrates. These strains play an important regulatory role in the mammalian gut ecosystem, influencing host health in multiple ways, including maintaining microbial community balance, promoting digestion and absorption, inhibiting the growth of harmful bacteria, and enhancing host immunity. Due to their good safety profile and stable physiological functions, Bifidobacteria animalis has long been extensively studied and applied in animal nutrition, pet food, feed additives, intestinal conditioning products, and veterinary clinical adjuvant therapy.

Morphologically

Bifidobacteria animalis are short rod-shaped or slightly curved, with a typical branching morphology, often appearing as "Y" or "V" shaped branching structures under a microscope. They are extremely sensitive to oxygen and therefore mostly live in the anaerobic environment of the animal gut. Their physiological characteristics include the ability to utilize various oligosaccharides and dietary fiber, producing short-chain fatty acids through fermentation. These metabolites can lower the intestinal pH, thereby inhibiting the growth of pathogenic bacteria such as Salmonella and Escherichia coli. In addition, short-chain fatty acids are an important energy source for animal intestinal epithelial cells, promoting villus development and enhancing barrier function. Animal Bifidobacteria also participate in the synthesis of B vitamins and enhance animals' resistance to pathogens by adhering to the intestinal wall and stimulating the mucosal immune system.

Production Process

The industrial-scale production of Bifidobacterium animalis relies on bio-fermentation technology and strict live bacteria preservation processes. The production process generally includes strain expansion, anaerobic fermentation, centrifugal concentration, freeze-drying or spray-drying, and encapsulation preservation. Because Bifidobacterium is extremely sensitive to oxygen and temperature, oxygen content, water activity, and temperature must be strictly controlled during production and storage. To improve the stability of the finished product, companies typically use microencapsulation technology to ensure a high survival rate of live bacteria even under the high temperatures of feed processing and the acidic environment of the intestine. Before leaving the factory, the product undergoes colony-forming unit testing, activity assessment, and contamination control to ensure its safety and functionality.

Application

In practical applications, animal Bifidobacteria are widely used to improve animal intestinal health and growth performance. In animal husbandry, adding animal Bifidobacteria to feed can improve feed intake, increase feed conversion efficiency, reduce the incidence of diarrhea, and enhance the stress resistance of young animals during weaning. Bifidobacterium preparations are commonly used in pig, cattle, sheep, poultry, and aquaculture as a microecological regulation strategy to reduce antibiotic resistance. In pet food, animal Bifidobacteria are often added to canine and feline gastrointestinal conditioning products to reduce gastrointestinal sensitivity, improve constipation and diarrhea, reduce fecal odor, and maintain long-term intestinal flora stability in pets. In veterinary clinics, Bifidobacterium animalis can be used to assist in managing indigestion, acute enteritis, or gut microbiota imbalance caused by drug treatment, providing animals with a gentle and safe intestinal support program.

With in-depth research into animal gut microbiota, the role of Bifidobacterium animalis in modern animal husbandry, pet nutrition, and veterinary health management is becoming increasingly prominent. As an important representative of probiotics, it can improve animal health and production performance while reducing the risks associated with antibiotic use. In the future, with the development of molecular breeding, precision nutrition, and gut microbiome analysis technologies, the application of Bifidobacterium animalis will become more precise and efficient, playing a more significant role in promoting animal health, improving farming efficiency, and driving green farming practices.

Industrial Chain

The upstream of the Bifidobacterium animalis industry chain mainly includes strain preservation institutions, culture medium and fermentation raw material suppliers, and bioreactor and freeze-drying equipment manufacturers. Representative upstream units include the American Type Culture Collection (ATCC), the China Center for Type Culture Collection (CCTCC), OXOID culture media, Sartorius fermentation equipment, and Boyikang freeze-drying equipment manufacturers. These companies provide strain sources, key culture medium components, and production equipment. Downstream applications are concentrated in large feed groups, livestock breeding enterprises, pet food companies, and veterinary drug companies, which are the core drivers of demand for Bifidobacterium animalis. Typical customers include CP Group, Wens Foodstuff Group, Haid Group Feed, Mars Petcare, and many domestic animal health product manufacturers. Downstream demand mainly comes from animal gut microbiota regulation, the promotion of antibiotic substitution policies, and the rapid growth of the pet nutrition sub-sector. Demand is particularly strong in the livestock breeding industry, especially in controlling weaning diarrhea and improving feed conversion rates in pigs, poultry, and ruminants. In the pet sector, the rapid growth of high-value-added probiotic formula foods driven by consumption upgrades has become a fast-growing sub-market.

Industry Policies

In terms of policy, countries worldwide are generally strengthening regulations on probiotics as feed additives, microecological preparations, and food ingredients. The EU uses EFSA for rigorous evaluation of microbial feed additives, requiring testing for strain safety, genetic stability, and resistance genes. The US FDA manages probiotics based on GRAS and pet food regulations, requiring animal microbial preparations to comply with safety and production standards. China has implemented the "Safety Use Standards for Feed Additives," "Veterinary Drug GMP," and the Ministry of Agriculture and Rural Affairs' approval system for probiotics, restricting antibiotic use and promoting the substitution of microecological preparations, significantly driving industry expansion. Japan and South Korea have relatively mature FOSHU and health functional food systems for food-grade probiotics. The overall policy direction is to improve the safety standards of animal microbial products, encourage antibiotic substitution, and enhance product registration and production standardization.

Development Trends

Industry development trends are reflected in the precision of strains, the formulation of highly active products, the widespread adoption of compound microbial products, and the expansion of application scenarios from traditional feed to pets, high-end farming, and disease control. With advancements in animal gut microbiota research, the functions of Bifidobacterium animalis have been more finely categorized, such as immunomodulatory, anti-diarrheal, and acid- and bile-resistant strains, leading to an increase in highly active and targeted functional products. Driving factors include the continued implementation of antibiotic-free policies in the global livestock industry, the rapid development of the pet market, stricter standards for animal health and food safety, and increased demand for cost reduction and efficiency improvement in the livestock industry. Obstacles include high technical barriers to strain development, stringent requirements for freeze-drying stability, insufficient industry standardization, weak R&D capabilities of small and medium-sized enterprises, and long registration cycles due to strict efficacy certification requirements for probiotics in some regions. Furthermore, upstream strain patent barriers and reliance on international strain resources also pose limitations.

Barriers to Entry

Entry barriers mainly include strain resource protection, fermentation and freeze-drying technology capabilities, regulatory registration thresholds, and application verification cycles. High-quality Bifidobacterium animalis strains typically require clear origins, intellectual property protection, and clinical or farm functional verification; new entrants lacking strain resources find it difficult to establish themselves. On the production side, mastery of high-density fermentation, stable freeze-drying protection systems, and the tolerance of bacteria in feed processing is required, placing high demands on processes and equipment. Regarding regulatory barriers, the registration procedures for microbial feed additives and veterinary drug preparations are complex and time-consuming in different countries, creating entry restrictions. Downstream customers are sensitive to product stability, efficacy, and cost, and require long-term demonstration trials, further increasing the difficulty of market entry. Overall, the Bifidobacterium animalis industry is in a growth phase against the backdrop of global antibiotic bans and the development of probiotic preparations. However, its technology-intensive nature, strict regulations, and complex application validation make the industry characterized by high entry barriers and steady growth.

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Bifidobacterium Animalis market is segmented as below:
By Company
Novonesis
IFF
Lallemand Health Solutions
Sacco System
Yili Group
Wecare Probiotics
Morinaga Milk Industry
Wisbiom (Beijing) Biotechnology
ATCC
ADM
Creative Biolabs
SynBalance
BGI Nutri
Microbiologics
Probi AB
Probioway
Bio-Growing

Segment by Type
Bifidobacterium Animalis Subsp. Lactis
Bifidobacterium Animalis Subsp.

Segment by Application
Food
Medicine and Health Products
Clinical Auxiliary Treatment
Animal Feed
Other

Each chapter of the report provides detailed information for readers to further understand the Bifidobacterium Animalis market:

Chapter 1: Introduces the report scope of the Bifidobacterium Animalis report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Bifidobacterium Animalis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Bifidobacterium Animalis market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Bifidobacterium Animalis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Bifidobacterium Animalis in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Bifidobacterium Animalis competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Bifidobacterium Animalis comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Bifidobacterium Animalis market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.

Other relevant reports of QYResearch:
Global Bifidobacterium Animalis Market Research Report 2025
Global Bifidobacterium Animalis Market Outlook, In‐Depth Analysis & Forecast to 2031
Global Bifidobacterium Animalis Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Bifidobacterium Animalis Subsp. Lactis Market Research Report 2025
Global Bifidobacterium Animalis Subsp. Lactis Market Outlook, In‐Depth Analysis & Forecast to 2031
Bifidobacterium Animalis Subsp. Lactis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Global Bifidobacterium Animalis Subsp. Lactis Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

This release was published on openPR.